Orion Corporation: Finland's undiscovered pharmaceutical champion with strong growth
Reading Time: 3 minutes
• Strong growth: Orion surpasses the forecast for 2024 with €1.542 billion in revenue and particularly benefits from the success of the prostate cancer drug Nubeqa. • Focus on innovation: New partnerships, including a collaboration with Invenra, drive the development of bispecific antibodies and CNS therapies forward. Although Orion is widely known as a constellation, the Finnish pharmaceutical company is still relatively unknown – yet the company performs impressively operationally and financially. In the past fiscal year 2024, Orion...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
